Mycoplasma Testing Market Size 2024-2028: Key Insights and Growth Trends

The mycoplasma testing market is forecast to grow by USD 743.4 million at a CAGR of 12.68% from 2023 to 2028. The market’s growth is attributed to increased emphasis on research and development in biopharmaceuticals, the expanding geriatric population, and the rising adoption of real-time mycoplasma testing. Advancements in technology and the demand for innovative biological safety testing products are further driving the market's expansion.

For more details about the industry, get the PDF sample report for free

Mycoplasma Testing Market Segmentation

The mycoplasma testing market report provides comprehensive data on various segments across regions, with forecasts and estimates for the period 2024-2028.

End-User Segments:

• Pharmaceutical and biotechnology companies
• Cell banks
• Academic research institutes
• Contract Research Organizations (CROs)
• Others

Product Segments:

• Consumables
• Systems

Geography:

• North America:
  • Canada
  • US
• Europe:
  • Germany
  • UK
• Asia:
  • China
• Rest of World (ROW)

The pharmaceutical and biotechnology companies segment is expected to drive significant growth during the forecast period.

Market Dynamics

Drivers

• Biopharmaceutical R&D Focus: The growing focus on research and development in biopharmaceuticals is a key driver for market growth. The biotechnology industry’s reliance on cell culture technology for drug discovery and biologics production increases the demand for mycoplasma testing.
• Geriatric Population Expansion: The increasing geriatric population contributes to the demand for mycoplasma testing in medical diagnostics and therapeutics.
• Real-time Testing Adoption: Real-time mycoplasma testing is gaining popularity due to its ability to provide fast and accurate results, ensuring the safety and quality of biopharmaceutical products.

Trends

• Strategic Alliances: Companies in the mycoplasma testing market are increasingly forming strategic alliances, partnerships, and collaborations to meet growing demand. For example, Agathos Biologics announced in April 2023 that it would offer analytical testing services to life science researchers, utilizing QIAcuity instrumentation and assays from QIAGEN.

Get more details by ordering the complete report

Challenges

• High Cost of Testing Products: One of the major challenges for the market is the high cost of mycoplasma testing products, particularly advanced kits, which can range from USD 990 to USD 5,500. These costs may limit adoption, especially among smaller companies or research labs with limited budgets.

Key Players

• Agilent Technologies Inc.
• ATCC
• Akron Biotechnology LLC
• Becton Dickinson and Co.
• Bio Techne Corp.
• Bionique Testing Laboratories Inc.
• Charles River Laboratories International Inc.
• DiaSorin SpA
• Dilarus GmbH
• F. Hoffmann La Roche Ltd.
• GeneCopoeia Inc.
• InvivoGen Corp.
• Lonza Group Ltd.
• Merck KGaA
• Norgen Biotek Corp.
• PromoCell GmbH
• Sartorius AG
• ScienCell Research Laboratories Inc.
• SGS SA
• Thermo Fisher Scientific Inc.

Future Market Insights

The mycoplasma testing market is expected to continue its growth trajectory, driven by the increasing adoption of cell culture technologies and the growing demand for biopharmaceuticals. The need for stringent microbiological monitoring in biotechnology and pharmaceuticals is expected to keep driving innovation in mycoplasma detection technologies, improving product safety and efficacy across various industries.